English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

In this study, production cross–section calculations of  32 P,  117 Sn,  153 Sm and  186,188 Re radionuclides used in bone pain palliation treatment produced by  30 Si(d,γ) 32 P,  118 Sn(γ,n) 117 Sn,  116 Sn(n,γ) 117 Sn,  150 Nd(α,n) 153 Sm,  154 Sm(n,2n) 153 Sm,  152 Sm(n,γ) 153 Sm,  186 W(d,2n) 186 Re,  187 Re(γ,n) 186 Re,  185 Re(n,γ) 186 Re and  187 Re(n,γ) 188 Re reactions have been investigated in the different incident energy range of 0.003–34 MeV. Two-component exciton and generalised superfluid models of the TALYS 1.6 and exciton and generalised superfluid models of the EMPIRE 3.1 computer codes have been used to pre-equilibrium (PEQ) reaction calculations. The calculated production cross–section results have been compared with available experimental results existing in the experimental nuclear reaction database (EXFOR). Except the  118 Sn(γ,n) 117 Sn,  150 Nd(α,n) 153 Sm and  185 Re(n,γ) 186 Re reactions, the two-component exciton model calculations of TALYS 1.6 code exhibit generally good agreement with the experimental measurements for all reactions used in this present study.

Production cross–section calculations of medical 32 P, 117 Sn, 153 Sm and 186,188 Re radionuclides used in bone pain palliation treatment